# Characterization of JC Papovavirus Adapted to Growth in Human Embryonic Kidney Cells

# TATSUO MIYAMURA,<sup>†</sup> KUNITO YOSHIIKE, AND KENNETH K. TAKEMOTO\*

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20205

Human papovavirus JC virus was adapted to growth in human embryonic kidney (HEK) cells. After eight passages, the HEK-adapted JC virus produced high virus yields and was capable of forming plaques in HEK monolayer cultures. Eleven plaque-purified stocks were prepared and characterized. Biologically, the plaque-purified virus induced tumor and viral antigens in HEK cells earlier and in a higher percentage of cells than uncloned virus. Cytopathic changes were also evident sooner and were more extensive. The DNA from uncloned as well as plaque-purified isolates was analyzed by restriction endonuclease cleavage followed by gel electrophoresis. The DNA from uncloned HEK-adapted virus was heterogeneous. Plaque-purified virus isolates yielded DNA which, although much less heterogeneous than the uncloned stock, still consisted of two or more species of viral DNA.

It is well established that the human papovavirus JC virus (JCV) has a highly restricted host range. Efficient replication with high virus yields has been observed only in primary human fetal glial (PHFG) cells, which have a high proportion of spongioblasts (12). Since the original isolation of JCV in 1971 (13), other strains have been recovered from brain tissue of patients with progressive multifocal leukoencephalopathy (1, 2, 14, 17). Without exception, all isolations were made in PHFG cells, and attempts to culture the virus in a variety of other types of cells were unsuccessful (12).

We recently reported on the replication of JCV in human amnion cells, but the yields were not comparable to those achieved in PHFG cells (16). In a continuation of these studies exploring other, more readily available cells for their ability to support JCV replication, we have successfully adapted JCV to growth in human embryonic kidney (HEK) cells. Biological and biochemical differences were noted in the adapted strain (JCV-HEK) compared with the wild-type MAD-1 strain propagated in PHFG cells. The most notable biological difference was the ability of the HEK-grown virus to form plaques. These results are reported in this communication.

## MATERIALS AND METHODS

Cells. HEK cells were purchased from Microbiological Associates, Rockville, Md., and were used at passages 2 through 5. Cells were maintained in Eagle minimum essential medium supplemented with 5% fetal bovine serum.

t Present address: Department of Enteroviruses, National Institute of Health, Musashi-Murayama, Tokyo 190-12, Japan.

Virus. Prototype JCV (MAD-1) was obtained from B. Padgett and propagated in PHFG cells. The stock virus had a hemagglutination (HA) titer of 320 U/0.2 ml.

Plaque formation. Monolayer cultures of HEK cells in 60-mm plastic dishes were inoculated with 0.5 ml of serial 10-fold dilutions of JCV-HEK. After <sup>1</sup> h of adsorption, the cultures were overlaid with 5 ml of medium containing 0.9% agarose and Eagle medium with 5% fetal bovine serum. Additional overlay medium was added at 5 and 12 days; the cultures were stained with medium containing 0.005% neutral red after 3 weeks.

Serological tests. For fluorescent-antibody tests, the indirect procedure was used, employing fluorescein-conjugated goat anti-hamster and anti-rabbit globulin. HA and HA inhibition tests were performed with human type 0 erythrocytes at 4°C. JCV antiserum was prepared by inoculating rabbits intravenously with 5,000 HA units of purified virus. The rabbits were bled and serum was collected 2 weeks after inoculation. Anti-JC T-antibody was obtained from hamsters bearing JCV tumors.

Virus purification. Infected cells which detached and floated in the medium were collected by centrifugation at 3,000 rpm. When cultures showed extensive cytopathic effects, the cells were removed by scraping and added to the previously collected, floating infected cells. The cells were suspended in 0.25% trypsin and 0.02% EDTA. Sodium deoxycholate (1% final concentration) was added to lyse the cells. After incubation at 37°C for 30 min, the suspension was clarified by centrifugation at 10,000 rpm for 10 min. The supernatant fluid was layered onto a 3-ml cushion of cesium chloride (1.34 g/ml) and centrifuged for 2 h at 35,000 rpm in an SW40 rotor. The virus band which formed below the interface was removed, and the virus was purified by isopycnic banding in cesium chloride in an SW50.1 rotor at 35,000 rpm for 18 h. The virus band was removed and dialyzed against phosphate-buffered saline (pH 7.2) for 12 h.

Preparation of JCV DNA. JCV-HEK DNA was prepared by the method of Hirt (5) from infected cells which had been collected as described for virus purification. Supercoiled form <sup>I</sup> DNA was isolated by the dye (ethidium bromide)-buoyant density method (15). JCV (MAD-1) DNA, used as a reference, was extracted from purified virions grown in PHFG cells. The MAD-1 strain used in this experiment was from <sup>a</sup> virus stock which yielded homogeneous viral DNA and was a generous gift from B. Padgett.

Cleavage of JCV DNA with restriction endonucleases. Besides enzymes and DNA, the reaction mixtures contained <sup>100</sup> mM Tris-hydrochloride (pH 7.5), 50 mM NaCl, and 5 mM MgCl<sub>2</sub> for  $EcoRI$  (New England BioLabs, Beverly, Mass.), <sup>20</sup> mM Tris-hydrochloride (pH 8.0), 100 mM NaCl, and 7 mM  $MgCl<sub>2</sub>$  for BamHI (Bethesda Research Laboratories, Inc., Rockville, Md.), and <sup>7</sup> mM Tris-hydrochloride (pH 7.5), <sup>60</sup> mM NaCl, 7 mM MgCl<sub>2</sub>, and 100  $\mu$ g of bovine serum albumin per ml for HindIII (New England BioLabs). The mixtures were incubated at  $37^{\circ}$ C for 30 min for EcoRI or 60 min for BamHI and HindIII.

The uncleaved and cleaved DNA samples  $(25 \mu l)$ were adjusted to 8% sucrose and 0.025% bromophenol blue and subjected to electrophoresis in 1.2% agarose slab gels at 21°C. The running Tris-borate buffer (pH 8.2) contained <sup>89</sup> mM Tris, <sup>89</sup> mM boric acid, and 2.5 mM EDTA. Gels were stained by soaking in Trisborate buffer with  $1 \mu$ g of ethidium bromide per ml for about <sup>20</sup> min. DNA bands were visualized and photographed on <sup>a</sup> short-wave length UV transilluminator. The six HindIII fragments of simian virus 40 (SV40) DNA were used as molecular weight standards.

# **RESULTS**

JCV replication in HEK cells. HEK cells grown on cover slips were infected with <sup>80</sup> HA units of prototype JCV (MAD-1). After 30 min of adsorption at 37°C, Eagle medium with 5% serum was added. At various times after infection, cover slips were removed, air dried, and fixed in acetone-methanol (1:1). The cells were then stained for tumor (T)- and viral (V)-antigens. The results of this test are shown in Table 1. A few cells were positive for T-antigen <sup>10</sup> days after infection, but were negative for V-antigen. Two weeks after infection, there was an increase in the number of T-antigen-positive cells, and a small percentage (0.5%) of the cells were also positive for V-antigen. The percentage of cells which stained for both types of.antigens continued to increase with time, and, by 25 days, 30% of the cells were positive for T-antigens and 10% were positive for V-antigen. Cultures in 75-cm<sup>2</sup> flasks which had been infected at the same time were also observed carefully for cytopathic effect, but no distinctive changes were noted and the cultures appeared healthy. However, numerous floating cells were seen above the monolayer of healthy cells 2 to 3 weeks after infection. These were collected by centrifugation when-

TABLE 1. JCV T- and V-antigen synthesis in HEK cells

Passage 1 <sup>ª</sup>		Passage 2		Passage 3	
т	v	т	v	т	v
0	0	20	0.5	10	$\boldsymbol{2}$
0.3	0	20	1	50	25
10	0.5	40	10	75	50
25	5	80	25	80	50
30	10	90	30	ND	<b>ND</b>
30	5	ND	ND	ND	ND

<sup>a</sup> Inoculum: first passage, <sup>80</sup> HA units; second passage, <sup>160</sup> HA units; third passage, <sup>160</sup> HA units. Data indicate percent positive cells. ND, Not done.

ever the medium was changed. After 2 months, the floating cells were pooled, sonicated briefly, and treated with <sup>50</sup> U of receptor-destroying enzyme for 18 h at 37°C. After centrifugation for 5 min at 3,000 rpm, the supernatant was tested for HA activity and found to be positive at <sup>a</sup> titer of 160 U/0.2 ml. The hemagglutinin was inhibited by JCV but not by BK virus antiserum.

Further serial passages in HEK cells were made, following the same procedure described above. T- and V-antigens were detected as early as 5 days on the second passage, and by 25 days, 90% of the cells were positive for T-antigens and 30% were stained by V-antigens (Table 1). By the third passage, 50% of the cells were positive for V-antigen by 15 days, whereas most of the cells now stained for T-antigens (Fig. 1). Cytopathic effect was detected by 5 to <sup>7</sup> days. The cellular changes consisted of scattered, round, highly refractile cells. Bizarre-shaped as well as giant cells were also observed. These cells became detached and floated in the medium.

In PHFG cells infected with JCV, the hemagglutinin is strongly cell associated and is rarely found in the supernatant fluid (12). By contrast, after seven passages in HEK, JCV hemagglutinin was detected in the supernatant fluid with titers of 1:80 to 1:320. Most of the virus still remained cell associated, and purified banded virus was obtained from infected cells according to the procedure described in Materials and Methods. The yields of JCV varied, depending on the quality of the HEK cells available. With exceptional cultures, it was possible to obtain virus yields of 150  $\mu$ g per 150-cm<sup>2</sup> flask. Examination of purified virions by electron microscopy revealed typical papovavirus particles.

Plaque formation of JCV-HEK. After eight passages, attempts were made to develop a plaque assay for JCV in HEK cells. Discrete plaques measuring <sup>1</sup> to <sup>3</sup> mm developed after <sup>3</sup> weeks (Fig. 2). Several stocks of JCV-HEK were assayed, and the titers ranged from  $2 \times 10^3$  to  $4.5 \times 10^4$ /ml. By contrast, the prototype MAD-



FIG. 1. Immunofluorescent staining of T-antigens (A) and V-antigens (B) in JCV-infected HEK cells. Cover slip cultures ofHEK cells were infected with JCV-HEK, passage 3. Cells were stained <sup>15</sup> days after infection. Magnification, x640.



FIG. 2. Plaque formation of JCV in HEK cells. Plates were inoculated with  $10^{-2}$  dilution (A) and  $10^{-3}$ dilution (B) of JCV-HEK.

<sup>1</sup> strain, which had been grown only in PHFG cells, failed to produce plaques in HEK cells even at high virus concentrations. The progeny from 11 different plaques were picked, and stocks were prepared. These plaque-purified stocks were identified as JCV by HA inhibition

and fluorescent-antibody tests using monospecific antiserum. Fluorescent-antibody tests of plaque-purified stocks for their ability to induce T- and V-antigens revealed that these antigens were detected much earlier and the intensity of staining was greater (Table 2). Furthermore,

TABLE 2. Induction of T- and V-antigens by plaque isolates in HEK cells

JCV plaque iso-		% Positive cells <sup>a</sup>		
late	HA titer	т		
<b>Pl-3</b>	1.280	70	50	
$Pl-4$	160	50	25	
<b>Pl-5</b>	640	50	30	
<b>Pl-6</b>	1,280	60	40	
$Pl-7$	160	70	40	
<b>Pl-9</b>	640	70	30	
<b>Pl-10</b>	160	70	40	
$Pl-12$	160	40	5	

<sup>a</sup> Percent positive cells 4 days after infection.

cytopathic effects appeared sooner and were more extensive. Cytoplasmic vacuolization was frequently observed.

Restriction enzyme analysis of JCV-HEK DNA. (i) Uncloned JCV-HEK. HEK cells infected with passage-9 virus were extracted for viral DNA ( $JCV-HEK P_{10}$ ) by employing Hirt's procedure (5). Uncleaved viral DNAs as well as DNAs cleaved with HindIII were analyzed by agarose gel electrophoresis together with DNA from JCV (MAD-1) grown in PHFG cells. SV40 and BK virus DNAs were included for comparison. Uncleaved form I JCV-HEK  $P_{10}$  DNA formed a broad band which migrated faster than SV40 or JCV (MAD-1) DNA (Fig. 3A). JCV (MAD-1) DNA yielded three fragments after HindIII digestion, A (4,480 base pairs [bp]), B (440 bp), and C (230 bp) as reported previously by Martin et al. (9). By contrast, the HindIII fragments of JCV-HEK  $P_{10}$  were very different (Fig. 3B). Fragments B and C could be found, but full-sized A fragments were not. There were multiple bands between the positions for fragments A and B. The C fragment, presumably containing the origin of DNA replication (8), appeared to be enriched. These results indicate that the passage 10 virus consisted of a heterogeneous population of virions as reported previously for JCV grown in PHFG cells (9) or human amnion cells (16). Similar results were obtained with another DNA sample from passage 9.

(ii) Plaque-purified JCV-HEK. DNA was prepared from HEK cells infected with <sup>11</sup> different stocks of plaque-purified JCV. Figure 4 shows the electrophoretic patterns of uncleaved DNAs. Some of them formed a single sharp band only (P1-3, 6), or with minor bands (P1-4, 7). Others formed multiple or broader bands (Pl-5, 8, 9, 10, 12, 17, 20). The DNA bands from all plaque isolates moved faster than the form <sup>I</sup> DNA of SV40 or JCV (MAD-1). Figure <sup>5</sup> shows electrophoretic patterns of representative DNAs cleaved with EcoRI and BamHI. Digestion with EcoRI revealed that most of the DNAs from plaque-purified JCV were susceptible to this enzyme. Only P1-12 and 20 contained EcoRIresistant fractions in detectable amounts (data not shown for P1-20). All of the EcoRI-cleaved DNAs moved faster than the SV40 DNA (Fig. 5) or JCV (MAD-1) linear DNA (data not shown), indicating that they were of shorter length. Digestion with BamHI showed that the DNAs tested (P1-3, 4, 5, 6, 7, and 8) were composed of susceptible and resistant fractions. These results indicate that the DNAs from plaque-purified JCV contain at least two species of DNA.

The *HindIII* cleavage patterns of the plaque isolates were simpler than that of the uncloned JCV-HEK DNA (Fig. 3), but differed from each other as well as from JCV (MAD-1). Figure 6 shows the representative cleavage patterns. As noted for the uncloned DNA, none of the DNAs from plaque-purified virus contained full-length A fragments. All the DNAs except P1-3 generated two fragments of 2,800 to 3,000 bp and two fragments at positions for B and C fragments. In addition they produced fragments differing in size (600 to 1,200 bp) and quantity with each isolate. Since the full length of JCV DNA is



FIG. 3. DNA from JCV-HEK. (A) Uncleaved DNAs; SV40 (lane 1), JCV (MAD-I) (lane 2), and  $JCV-HEK$   $P_{10}$  (lane 3). Electrophoresis was done at <sup>130</sup> V for <sup>190</sup> min. (B) HindIII-cleaved DNAs; SV40 (lane 4), JCV (MAD-I) (lane 5), JCV-HEK (lane 6), and BK virus (lane 7). Electrophoresis was done at .100 V for <sup>190</sup> min. SV40 and BK virus DNAs were prepared from infected CV-1 (TC7) and HEK cells, respectively.



FIG. 4. DNA from plaque-purified JCV. DNAs of SV40 (lane 1); JCV-HEK (Pl-4 (lane 2); Pl-7 (lane 3); Pl-10 (lane 4); Pl-12 (lane 5); JCV (MAD-1) (lane 6); JCV-HEK  $P_{10}$ , uncloned (lane 7); Pl-3 (lane 8); Pl-6 (lane 9); Pl-20 (lane 10); Pl-5 (lane 11); Pl-8 (lane 12); P1-9 (lane 13); and Pl-17 (lane 14) were subjected for electrophoresis at <sup>130</sup> Vfor <sup>190</sup> min. Arrows indicate the positions for forms I, II, and III of SV40 DNA. JCV (MAD-1) apparently contained some defective DNA.



FIG. 5. Digestion of plaque-purified JCV DNA with endonucleases EcoRI and BamHI. Arrows indicate the positions for forms I, II, and III of SV40 DNA. (A) Digestion with EcoRI. Digested DNAs of SV40 (lane 1), JCV-HEK Pl-4 (lane 2), Pl-7 (lane 3), Pl-10 (lane 4), and Pl-12 (lane 5) were subjected to electrophoresis at <sup>130</sup> V for <sup>240</sup> min. (B) with BamHI. Digested DNAs of SV40 (lane 6), JCV-HEK Pl-3 (lane 7), Pl-4 (lane 8), Pl-5 (lane 9), and Pl-6 (lane 10) were subjected to electrophores for 240 min. The JCV DNA, which migrated more slowly than form III SV40 DNA, is form I DNA uncleaved with BamHI.

about  $5,100$  bp (9), the two  $2,800$ - to  $3,000$ -bp DISCUSSION fragments must have originated from molecules.

Figure 6 also shows the  $HindIII + EcoRI$ cleavage patterns of DNAs from JCV and the representative plaque isolates. JCV  $(MAD-1)$  DNA has an  $EcoRI$ -susceptible site within the HindIII A fragment (9); therefore, combined digestion with the two enzymes gen-

erated four fragments,  $A_1$  (2,820 bp),  $A_2$  (1,620 bp), B  $(440$  bp), and C  $(230$  bp), as shown in Fig. 6, lane 6. The plaque isolates were found to contain the fragments corresponding to  $A_1$  and  $A_2$  in size, although in Pl-17 (data not shown) and Pl-20 (Fig. 6, lane 15) the amount of  $A_1$ fragments was reduced considerably. From the sizes of  $A_1$  and  $A_2$  fragments, they must have originated from different 2,800- to 3,000-bp fragments of HindIII. The combined digestion also showed that the 2,800-bp fragments of P1-3 consisted of two DNAs, EcoRI-cleaved and uncleaved.

In an attempt to produce homogeneous stocks, B JCV Pl-3 and 6 were passaged at very low multiplicities of infection (1 to <sup>10</sup> HA units per culture). After a long period of 2 months for complete cell lysis, the viral DNAs were analyzed. The HindIII and  $HindIII + EcoRI$  cleavage patterns were identical with those of DNAs obtained at higher multiplicities of infection.

> Some of the plaque-purified stocks (P1-4, 7, 10, and 12) were replaqued on HEK cells, and seven new plaques were isolated. All the DNAs from the newly isolated stocks had the same common characteristics described above. Digestion with HindIII produced two large fragments of 2,800 to 3,000 bp, the B and C fragments, and other fragments which differed from sample to sample. Although the viral DNAs lacked HindIII A fragments, they were revealed to have  $A_1$  and  $A_2$  fragments after EcoRI digestion. The cleavage patterns of the two new isolates originating from Pl-4 and 7 resembled those of Pl-6.

In a previous report  $(12)$ , it was shown that JCV has an extremely restricted host range and that the original prototype virus, MAD-1 strain, replicated well only in PHFG cells; HEK cells did not support the growth of this virus. Limited growth of JCV was observed in human amnion cells (16). Attempts to circumvent the block in viral replication through the use of viral DNA



FIG. 6. Cleavage of plaque-purified JCV DNA with HindIII and with EcoRI + HindIII. Electrophoresis was done at <sup>100</sup> V for <sup>190</sup> min. Lane 1, SV40 DNA (digested with HindIII); lane 2, JCV (MAD-1) DNA (HindIII); lane 3, JCV-HEK Pl-4 DNA (HindIII); lane 4, Pl-7 DNA (HindIII); lane 5, SV40 DNA (HindIII); lane 6, JCV (MAD-1) DNA (EcoRI + HindIII); lane 7, Pl-4 DNA (HindIII + EcoRI); lane 8, Pl-7 DNA (EcoRI + HindIII); lane 9, SV40 DNA (HindIII); lane 10, Pl-3 DNA (HindIII); lane 11, Pl-3 DNA (EcoRI + HindIII); lane 12, Pl-6 DNA (HindIII); lane 13, Pl-6 DNA (EcoRI + HindIII); lane 14, Pl-20 DNA (HindIII); lane <sup>15</sup> Pl-20 DNA (EcoRI + HindIII).

in transfection studies using HEK cells also failed (4). We have found that although HEK cells are quite resistant to JCV, the virus can be adapted to growth in these cells, and after eight passages, relatively high yields can be obtained. Furthermore, unlike the prototype virus, the adapted strain is capable of forming plaques in HEK cells. By several criteria, the virus was identified as JCV. These included standard HA inhibition and fluorescent-antibody tests using specific antisera, and restriction enzyme analysis of viral DNA.

JCV DNA obtained from virus grown in PHFG cells has been reported to be heterogeneous by several investigators (4, 6, 10, 11). Similarly, the JCV grown in HEK cells also yielded heterogeneous viral DNA, and surprisingly, the virus obtained after plaque purification again yielded DNA which, although considerably less heterogeneous than the parental virus, was not completely homogeneous. It thus appears that JCV is inherently unstable and continuously produces particles which contain DNA of various sizes. Although SV40, polyoma virus, and BK virus produce particles containing heterogeneous DNA which are defective (3, 7, 18), it is not clear whether such particles of JCV are also defective. In studying the infectivity of JCV DNA, Frisque et al. (4) did not find large differences in the infectivity of heterogeneous DNA as compared to homogeneous DNA preparations as far as their ability to induce viral antigens was concerned.

DNAs from plaque-purified JCV were slightly shorter than JCV (MAD-1) DNA and consisted of two or more species of DNA. Despite the lack of <sup>a</sup> full-length HindIII A fragment, most of the DNA from plaque-purified virus yielded  $A_1$  and  $A_2$  fragments probably originating from different DNA molecules upon combined digestion with HindIII and EcoRI. These characteristics were unchanged after low-multiplicity passage or after recloning by the plaque method. The results of these experiments suggest that the plaques may have been formed by complementation between defective particles. Alternatively, we postulate that there may be various viable deletion mutants in stocks adapted to growth in HEK cells. To determine which of these hypotheses is applicable, the various species of DNA must be isolated and characterized.

Although plaque-purified virus did not yield completely homogeneous DNA, its replication in HEK cells was more efficient and the growth cycle was considerably shortened. This was evident by the appearance of earlier, more extensive cytopathic effects and complete cell lysis, resulting in greater virus yields. Thus, plaquepurified JCV stocks will facilitate biological and biochemical studies of this interesting and important virus.

#### ACKNOWLEDGMENT

We dedicate this paper to the late Isamu Tagaya, National Institute of Health, Tokyo, Japan, in grateful appreciation of his many years of support and encouragement to T.M. and K.Y.

### LITERATURE CITED

- 1. Cathala, F., J.-J. Hauw, and R. Escourolle. 1973. Isolement et etude ultrastructurale d'un virus de type papova non neutralisé par le sérum de référence anti-SV40 au cours de la leucoencéphalopathie multifocale progressive. C. R. Acad. Sci. (Paris) 276:1081-1084.
- 2. Field, A. M., S. D. Gardner, R. A. Goodbody, and M. A. Woodhouse. 1974. Identity of a newly isolated human polyomavirus from a patient with progressive multifocal leucoencephalopathy. J. Clin. Pathol. 27: 341-347.
- 3. Fried, M. 1974. Isolation and partial characterization of different defective DNA molecules derived from polyoma virus. J. Virol. 13:939-946.
- 4. Frisque, R. J., J. D. Martin, B. L Padgett, and D. L. Walker. 1979. Infectivity of the DNA from four isolates of JC virus. J. Virol. 32:476-482.
- 5. Hirt, B. 1967. Selective extraction of polyoma DNA from infected mouse cell cultures. J. Mol. Biol. 26:365-369.
- 6. Howley, P. M., G. Khoury, K. K. Takemoto, and M. A. Martin. 1976. Polynucleotide sequences common to the genomes of simian virus 40 and the human papovaviruses JC and BK. Virology 73:303-307.
- 7. Howley, P. M., M. F. Mullarkey, K. K. Takemoto, and M. A. Martin. 1975. Characterization of human papovavirus BK DNA. J. Virol. 15:173-181.
- 8. Law, M. F., J. D. Martin, K. K. Takemoto, and P. M. Howley. 1979. The colinear alignment of the genomes of papovavirus JC, BK, and SV40. Virology 96:576-587.
- 9. Martin, J. D., R. J. Frisque, B. L. Padgett, and D. L. Walker. 1979. Restriction endonuclease cleavage map of the DNA of JC virus. J. Virol. 29:846-855.
- 10. Osborn, J. E., S. M. Robertson, B. L. Padgett, D. L. Walker, and B. Weisblum. 1976. Comparison of JC and BK human papovaviruses with simian virus 40:

DNA homology studies. J. Virol. 19:675-684.

- 11. Osborn, J. E., S. M. Robertson, B. L. Padgett, G. M. ZuRhein, D. L. Walker, and B. Weisblum. 1974. Comparison of JC and BK human papovaviruses with simian virus 40: restriction endonuclease digestion and gel electrophoresis of resultant fragments. J. Virol. 13: 614-622.
- 12. Padgett, B. L., C. M. Rogers, and D. L. Walker. 1977. JC virus, a human polyomavirus associated with progressive multifocal leukoencephalopathy: additional biological characteristics and antigenic relationships. Infect. Immun. 15:656-662.
- 13. Padgett, B. L., D. L. Walker, G. M. ZuRhein, R. J. Eckroade, and B. H. Dessel. 1971. Cultivation of papova-like virus from human brain with progressive multifocal leukoencephalopathy. Lancet i: 1257-1260.
- 14. Padgett, B. L., D. L Walker, G. M. ZuRhein, A. E. Hodach, and S. M. Chou. 1976. JC papovavirus in progressive multifocal leukoencephalopathy. J. Infect. Dis. 133:686-690.
- 15. Radloff, R., W. Bauer, and J. Vinograd. 1967. A dyebuoyant density method for the detection and isolation of closed circular duplex DNA: the closed circular DNA in HeLa cells. Proc. Natl. Acad. Sci. U.S.A. 58:1514- 1521.
- 16. Takemoto, K. K., P. M. Howley, and T. Miyamura. 1979. JC human papovavirus replication in human amnion cells. J. Virol. 30:384-389.
- 17. Weiner, L. P., 0. Narayan, J. B. Penny, R. M. Herndon, E. R. Feringa, W. W. Tourtellotte, and R. T. Johnson. 1973. Papovavirus of JC type in progressive multifocal leukoencephalopathy. Arch. Neurol. 29:1-3.
- 18. Yoshiike, K. 1968. Studies on DNA from low-density particles of SV40. I. Heterogeneous defective virions produced by successive undiluted passages. Virology 34:391-401.